Hypertrophic Cardiomyopathy in Review: Assessing SCD Risk in HCM & Managing HCM With High Risk SCD

Published: 26 September 2022

  • Views:

    Views Icon 14882
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


In this two-part hypertrophic cardiomyopathy (HCM) video series, Prof Perry Elliott discusses stratifying sudden cardiac death (SCD) risk in HCM patients and how to select treatment (ICD vs no ICD), including approach in primary prevention and secondary patients.


Supported through an educational grant from Bristol Myers Squibb

Learning Objectives

After watching this video, participants should be able to:

  • Stratify patients likely to benefit from invasive procedures versus pharmacological treatment using surrogate case data and apply to clinical practice
  • Choose appropriate medical treatment for HCM in simple and complex patient cases and implement into clinical practice

Target Audience

  • Cardiologists
  • Heart failure specialists
  • Allied healthcare professionals

More from this programme

Faculty Biographies

Perry Elliott

Perry Elliott

Professor in Inherited Cardiovascular Disease

Personal History

Professor Perry Mark Elliott was born on December 7, 1963, in London.6 He is a Professor of Cardiovascular Medicine at University College London (UCL) and a Senior Investigator of the UK National Institute for Health Research (NIHR). 

He is Director of the UCL Centre for Heart Muscle Disease, Head of Clinical Research at the Institute of Cardiovascular Science UCL and a consultant cardiologist in the Centre for Inherited Cardiovascular Disease at the Barts Heart Centre, St. Bartholomew's Hospital London, UK.3

Academic History1

Dr Elliott studied medicine at St. Thomas’s Hospital Medical School, London from 1982 to 1987.

After graduating in 1987 he trained in general medicine. In 1991 he became a member of the Royal College of Physicians and completed his general cardiology training at St. George’s Hospital Medical School, London.


View full profile